Advisors Asset Management Inc. Sells 196 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Advisors Asset Management Inc. reduced its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 3.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,787 shares of the biotechnology company’s stock after selling 196 shares during the period. Advisors Asset Management Inc.’s holdings in United Therapeutics were worth $1,715,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. ClariVest Asset Management LLC raised its position in United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 42 shares during the period. V Square Quantitative Management LLC bought a new position in shares of United Therapeutics during the second quarter valued at about $30,000. Innealta Capital LLC purchased a new position in shares of United Therapeutics in the second quarter worth about $33,000. USA Financial Formulas bought a new stake in shares of United Therapeutics in the 3rd quarter valued at about $33,000. Finally, Capital Performance Advisors LLP purchased a new stake in United Therapeutics during the 3rd quarter valued at about $82,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on UTHR. Wells Fargo & Company lifted their price target on United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 20th. Argus upped their price target on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Jefferies Financial Group increased their price target on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. Oppenheimer boosted their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Finally, HC Wainwright raised their target price on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $370.86.

United Therapeutics Stock Performance

Shares of United Therapeutics stock opened at $372.89 on Monday. The stock’s fifty day moving average is $365.06 and its 200 day moving average is $332.32. United Therapeutics Co. has a one year low of $208.62 and a one year high of $417.82. The stock has a market cap of $16.65 billion, a P/E ratio of 16.38, a P/E/G ratio of 1.08 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million for the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the previous year, the firm earned $5.38 EPS. The business’s quarterly revenue was up 22.9% on a year-over-year basis. Analysts predict that United Therapeutics Co. will post 25.22 EPS for the current year.

Insider Transactions at United Therapeutics

In related news, Director Nilda Mesa sold 224 shares of the business’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $412.28, for a total value of $92,350.72. Following the transaction, the director now directly owns 5,783 shares of the company’s stock, valued at approximately $2,384,215.24. The trade was a 3.73 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Paul A. Mahon sold 7,700 shares of the stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $367.36, for a total transaction of $2,828,672.00. Following the sale, the executive vice president now directly owns 36,710 shares of the company’s stock, valued at approximately $13,485,785.60. This trade represents a 17.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 117,227 shares of company stock valued at $43,671,320 over the last three months. Corporate insiders own 11.90% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.